CAV1 and neoplasm: In addition, low tumor Cav-1 in patients with GS 6 + 7 (10-year P-EFS 45 ± 17%) had significantly shorter cancer specific survival than those with high tumor Cav-1 in this subgroup (10-year P-EFS 79 ± 5%) (Fig 3B).